SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version.

the of Nuclear new for nuclear medicine to the science of nuclear medicine improve the quality of to abbreviated version of this most guideline with wide relevance to many practitioners and patients. The complete

[1]  Frederick D. Grant,et al.  A JOINT STATEMENT FROM THE AMERICAN THYROID ASSOCIATION. , 2021, Thyroid : official journal of the American Thyroid Association.

[2]  J. Jonklaas,et al.  Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document , 2021, European Thyroid Journal.

[3]  Lin Li,et al.  Low‐ and high‐dose radioiodine ablation for low‐/intermediate‐risk differentiated thyroid cancer in China: Large randomized clinical trial , 2021, Head & neck.

[4]  Shouluan Ding,et al.  A pre-ablative thyroid-stimulating hormone with 30–70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients , 2021, Scientific Reports.

[5]  A. Alibrandi,et al.  Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  J. Jonklaas,et al.  Evidence Based Use of LT4/LT3 Combinations in Treating Hypothyroidism: A Consensus Document. , 2020, Thyroid : official journal of the American Thyroid Association.

[7]  T. Fahey,et al.  Ablation therapy using a low dose of radioiodine may be sufficient in low- to intermediate-risk patients with follicular variant papillary thyroid carcinoma , 2020, The Journal of international medical research.

[8]  A. Avram,et al.  SNMMI Procedure Standard for Scintigraphy for Differentiated Thyroid Cancer , 2020, The Journal of Nuclear Medicine Technology.

[9]  B. Burkey,et al.  Salivary and lacrimal dysfunction after radioactive iodine for differentiated thyroid cancer: American Head and Neck Society Endocrine Surgery Section and Salivary Gland Section joint multidisciplinary clinical consensus statement of otolaryngology, ophthalmology, nuclear medicine and endocrinology , 2020, Head & neck.

[10]  P. Dong,et al.  Bone marrow suppression in pediatric patients with differentiated thyroid cancer following empirical radioiodine therapy , 2020, Medicine.

[11]  C. Reiners,et al.  Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey , 2020, Frontiers in Endocrinology.

[12]  M. Schäfers,et al.  Impact of FDG-PET on therapy management and outcome of differentiated thyroid carcinoma patients with elevated thyroglobulin despite negative iodine scintigraphy , 2020, Nuklearmedizin.

[13]  R. Görges,et al.  Longer-term recurrence rate after low versus high dose radioiodine ablation for differentiated thyroid Cancer in low and intermediate risk patients: a meta-analysis , 2020, BMC Cancer.

[14]  P. Trimboli,et al.  Radioiodine Ablation of Remaining Thyroid Lobe in Patients with Differentiated Thyroid Cancer Treated by Lobectomy: A Systematic Review and Metaanalysis , 2020, The Journal of Nuclear Medicine.

[15]  R. Kloos,et al.  Appropriate Use Criteria for Nuclear Medicine in the Evaluation and Treatment of Differentiated Thyroid Cancer , 2020, The Journal of Nuclear Medicine.

[16]  K. Bible,et al.  Bone metastases in thyroid cancer , 2020, Journal of bone oncology.

[17]  L. Duntas,et al.  MANAGEMENT OF ENDOCRINE DISEASE: The Role of rhTSH in the Management of Differentiated Thyroid Cancer: Pros and Cons. , 2019, European journal of endocrinology.

[18]  M. Luster,et al.  EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  D. van Nostrand,et al.  Advanced differentiated thyroid cancer: when to stop radioiodine? , 2019, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[20]  A. Miyauchi,et al.  Patient Experience of Thyroid Cancer Active Surveillance in Japan , 2019, JAMA otolaryngology-- head & neck surgery.

[21]  D. van Nostrand,et al.  Conventional Radioiodine Therapy for Differentiated Thyroid Cancer. , 2019, Endocrinology and metabolism clinics of North America.

[22]  P. Trimboli,et al.  PET/CT in thyroid nodule and differentiated thyroid cancer patients. The evidence-based state of the art , 2019, Reviews in Endocrine and Metabolic Disorders.

[23]  H. Steinert,et al.  Multidisciplinary approach for risk-oriented treatment of low-risk papillary thyroid cancer in Switzerland. , 2019, Swiss medical weekly.

[24]  A. Hackshaw,et al.  Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial , 2019, The lancet. Diabetes & endocrinology.

[25]  A. Iagaru,et al.  Diagnostic 123I Whole Body Scan Prior to Ablation of Thyroid Remnant in Patients With Papillary Thyroid Cancer: Implications for Clinical Management , 2018, Clinical nuclear medicine.

[26]  L. Stegger,et al.  177Lu-DOTATATE Therapy in Radioiodine-refractory Differentiated Thyroid Cancer: A Single Center Experience , 2018, Clinical nuclear medicine.

[27]  Lauren J. Beesley,et al.  Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer , 2018, Clinical nuclear medicine.

[28]  E. Hindié,et al.  Radioactive iodine ablation in low-risk thyroid cancer. , 2018, The lancet. Diabetes & endocrinology.

[29]  D. van Nostrand,et al.  Radioiodine Refractory Differentiated Thyroid Cancer: Time to Update the Classifications. , 2018, Thyroid : official journal of the American Thyroid Association.

[30]  A. Formenti,et al.  Possible delayed diagnosis and treatment of metastatic differentiated thyroid cancer by adopting the 2015 ATA guidelines. , 2018, European journal of endocrinology.

[31]  A. Avram,et al.  Thyroid cancer radiotheragnostics: the case for activity adjusted 131I therapy , 2018, Clinical and Translational Imaging.

[32]  M. Schlumberger,et al.  Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. , 2018, The lancet. Diabetes & endocrinology.

[33]  Tae Yong Kim,et al.  Changes in Serum Thyroglobulin Levels After Lobectomy in Patients with Low-Risk Papillary Thyroid Cancer. , 2018, Thyroid : official journal of the American Thyroid Association.

[34]  M. Amit,et al.  Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine , 2018, The Journal of clinical endocrinology and metabolism.

[35]  A. G. García Vicente,et al.  Low-Dose Radioiodine Ablation in Patients with Low-Risk Differentiated Thyroid Cancer , 2018, European Thyroid Journal.

[36]  M. Luster,et al.  Low or Undetectable Basal Thyroglobulin Levels Obviate the Need for Neck Ultrasound in Differentiated Thyroid Cancer Patients After Total Thyroidectomy and 131I Ablation. , 2018, Thyroid : official journal of the American Thyroid Association.

[37]  K. Burman,et al.  Use of 99mTc-sestamibi SPECT/CT when conventional imaging studies are negative for localizing suspected recurrence in differentiated thyroid cancer: a method and a lesson for clinical management , 2018, Endocrine.

[38]  D. van Nostrand,et al.  Radioiodine refractory differentiated thyroid cancer. , 2018, Critical reviews in oncology/hematology.

[39]  A. Avram,et al.  Location and Causation of Residual Lymph Node Metastasis After Surgical Treatment of Regionally Advanced Differentiated Thyroid Cancer. , 2018, Thyroid : official journal of the American Thyroid Association.

[40]  A. Alibrandi,et al.  Undetectable or low (<1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients , 2018, Oncotarget.

[41]  Maomei Ruan,et al.  Predicting 131I-avidity of metastases from differentiated thyroid cancer using 18F-FDG PET/CT in postoperative patients with elevated thyroglobulin , 2018, Scientific Reports.

[42]  D. Morrish,et al.  Comparison of 30 mCi and 50 mCi I-131 doses for ablation of thyroid remnant in papillary thyroid cancer patients , 2018, Endocrine research.

[43]  E. Cibas,et al.  The 2017 Bethesda System for Reporting Thyroid Cytopathology. , 2017, Journal of the American Society of Cytopathology.

[44]  E. Cibas,et al.  The 2017 Bethesda System for Reporting Thyroid Cytopathology. , 2017, Journal of the American Society of Cytopathology.

[45]  A. Nahum,et al.  Fixed 3.7-GBq 131I Activity for Metastatic Thyroid Cancer Therapy Ignores Science and History , 2017, The Journal of Nuclear Medicine.

[46]  Sung-Bae Kim,et al.  Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial , 2017, Thyroid : official journal of the American Thyroid Association.

[47]  B. Liu,et al.  Low versus high radioiodine activity for ablation of the thyroid remnant after thyroidectomy in Han Chinese with low-risk differentiated thyroid cancer , 2017, OncoTargets and therapy.

[48]  Gilles Russ,et al.  European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS , 2017, European Thyroid Journal.

[49]  R. Tuttle,et al.  Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell‐derived thyroid carcinoma , 2017, Cancer.

[50]  C. Nathan,et al.  Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma. , 2017, Thyroid : official journal of the American Thyroid Association.

[51]  E. Hindié,et al.  Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[52]  M. Plebani,et al.  Letter to the Editor: What Is the Role of Serum Thyroglobulin Measurement in Patients With Differentiated Thyroid Cancer Treated Without Radioactive Iodine? , 2017, The Journal of clinical endocrinology and metabolism.

[53]  M. Schlumberger,et al.  Reply: Comparison of Empiric Versus Dosimetry-Guided Radioiodine Therapy: The Devil Is in the Details , 2017, The Journal of Nuclear Medicine.

[54]  M. Luster,et al.  Comparison of Empiric Versus Dosimetry-Guided Radioiodine Therapy: The Devil Is in the Details , 2017, The Journal of Nuclear Medicine.

[55]  O. Schober,et al.  Evaluation of 131I scintigraphy and stimulated thyroglobulin levels in the follow up of patients with DTC: a retrospective analysis of 1420 patients , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[56]  E. Kim,et al.  Thyroid Cancer: A Comprehensive Guide to Clinical Management , 2017, The Journal of Nuclear Medicine.

[57]  A. Miyauchi,et al.  Low-risk papillary microcarcinoma of the thyroid: A review of active surveillance trials. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[58]  M. Sathekge,et al.  Higher preablative serum thyroid-stimulating hormone level predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma , 2017, Nuclear medicine communications.

[59]  M. Luster,et al.  The “reset button” revisited: why high activity 131I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[60]  A. Bahloul,et al.  A comparison of low versus high radioiodine administered activity in patients with low-risk differentiated thyroid cancer , 2017, European Archives of Oto-Rhino-Laryngology.

[61]  G. Sgouros,et al.  Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in 124I PET/CT–Based Dosimetry for 131I Therapy of Metastatic Differentiated Thyroid Cancer , 2017, The Journal of Nuclear Medicine.

[62]  Z. El-Sayed,et al.  Low-dose versus high-dose radioactive iodine ablation of differentiated thyroid carcinoma: a prospective randomized study , 2016 .

[63]  P. Vitti,et al.  Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation. , 2016, The Journal of clinical endocrinology and metabolism.

[64]  H. Ahn,et al.  Thyroid Cancer Screening in South Korea Increases Detection of Papillary Cancers with No Impact on Other Subtypes or Thyroid Cancer Mortality. , 2016, Thyroid : official journal of the American Thyroid Association.

[65]  J. Joung,et al.  Efficacy of Low-dose and High-dose Radioactive Iodine Ablation With rhTSH in Korean Patients With Differentiated Thyroid Carcinoma: The First Report in Nonwestern Countries , 2016, American journal of clinical oncology.

[66]  M. Banerjee,et al.  Use of imaging tests after primary treatment of thyroid cancer in the United States: population based retrospective cohort study evaluating death and recurrence , 2016, British Medical Journal.

[67]  He Lijuan,et al.  I-131 for Remnant Ablation in Differentiated Thyroid Cancer After Thyroidectomy: A Meta-Analysis of Randomized Controlled Evidence , 2016, Medical science monitor : international medical journal of experimental and clinical research.

[68]  Shu-qi Wu,et al.  Chinese Data of Efficacy of Low- and High-Dose Iodine-131 for the Ablation of Thyroid Remnant. , 2016, Thyroid : official journal of the American Thyroid Association.

[69]  T. Poeppel,et al.  68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG–Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin , 2016, The Journal of Nuclear Medicine.

[70]  Nosheen Fatima,et al.  Comparable Ablation Efficiency of 30 and 100 mCi of I-131 for Low to Intermediate Risk Thyroid Cancers Using Triple Negative Criteria. , 2016, Asian Pacific journal of cancer prevention : APJCP.

[71]  F. Mottaghy,et al.  Dose–Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT , 2016, The Journal of Nuclear Medicine.

[72]  B. Krause,et al.  Why the European Association of Nuclear Medicine has declined to endorse the 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[73]  C. Reiners,et al.  Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[74]  M. Plebani,et al.  Thyroglobulin measurement by highly sensitive assays: focus on laboratory challenges , 2015, Clinical chemistry and laboratory medicine.

[75]  J. Jonklaas,et al.  Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012. , 2015, The Journal of clinical endocrinology and metabolism.

[76]  W. Chung,et al.  Effect of a Low Iodine Diet vs. Restricted Iodine Diet on Postsurgical Preparation for Radioiodine Ablation Therapy in Thyroid Carcinoma Patients , 2015, Yonsei medical journal.

[77]  L. Morris,et al.  Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer. , 2015, Thyroid : official journal of the American Thyroid Association.

[78]  Amy Y. Chen,et al.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: THE INCREASING INCIDENCE OF THYROID CANCER. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[79]  Jun Liang,et al.  Low-dose radioiodine ablation in differentiated thyroid cancer with macroscopic extrathyroidal extension and low level of preablative-stimulated thyroglobulin , 2015, Nuclear medicine communications.

[80]  K. Wong,et al.  Preablation 131-I scans with SPECT/CT contribute to thyroid cancer risk stratification and 131-I therapy planning. , 2015, The Journal of clinical endocrinology and metabolism.

[81]  Sung-Bae Kim,et al.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. , 2015, The New England journal of medicine.

[82]  S. Roman,et al.  Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. , 2015, The Journal of clinical endocrinology and metabolism.

[83]  P. Vitti,et al.  Effects of radioiodine treatment for differentiated thyroid cancer on testis function , 2015, Clinical endocrinology.

[84]  J. Gerss,et al.  Differentiated Thyroid Cancer Patients More Than 60 Years Old Paradoxically Show an Increased Life Expectancy , 2015, The Journal of Nuclear Medicine.

[85]  Dongfeng Zhang,et al.  Low versus high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a meta-analysis of randomized controlled trials , 2015, Endocrine.

[86]  Charles D. Smith,et al.  Reversible cognitive, motor, and driving impairments in severe hypothyroidism. , 2015, Thyroid : official journal of the American Thyroid Association.

[87]  E. Palmer,et al.  Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib , 2014, Clinical Cancer Research.

[88]  C. Reiners,et al.  Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patients. , 2014, The Journal of clinical endocrinology and metabolism.

[89]  R. Paschke,et al.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial , 2014, The Lancet.

[90]  Michael Lassmann,et al.  The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[91]  Tae Yong Kim,et al.  Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension. , 2014, Thyroid : official journal of the American Thyroid Association.

[92]  M. Luster,et al.  Definition and management of radioactive iodine-refractory differentiated thyroid cancer. , 2014, The lancet. Diabetes & endocrinology.

[93]  P. Erba,et al.  Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients. , 2014, Thyroid : official journal of the American Thyroid Association.

[94]  L. Duntas,et al.  DIAGNOSIS OF ENDOCRINE DISEASE: Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper , 2014, European journal of endocrinology.

[95]  A. Fard-Esfahani,et al.  Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma , 2014, Nuclear medicine communications.

[96]  D. Gao,et al.  Postpartum breast involution reveals regression of secretory lobules mediated by tissue-remodeling , 2014, Breast Cancer Research.

[97]  G. Braunstein,et al.  Evolving approaches in managing radioactive iodine-refractory differentiated thyroid cancer. , 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[98]  R. Chan,et al.  Use of bisphosphonates and the risk of osteonecrosis among cancer patients: a systemic review and meta-analysis of the observational studies , 2014, Supportive Care in Cancer.

[99]  L. Ceriani,et al.  Detectable thyroglobulin with negative imaging in differentiated thyroid cancer patients , 2013, Nuklearmedizin.

[100]  A. Gill,et al.  Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma. , 2013, Surgery.

[101]  L. Duntas,et al.  Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. , 2013, Thyroid : official journal of the American Thyroid Association.

[102]  A. Piccardo,et al.  Thyroid lobe ablation with iodine-131 in patients with differentiated thyroid carcinoma: a randomized comparison between 1.1 and 3.7 GBq activities , 2013, Nuclear medicine communications.

[103]  A. Valachis,et al.  High versus low radioiodine activity in patients with differentiated thyroid cancer: A meta-analysis , 2013, Acta oncologica.

[104]  G. Cevenini,et al.  Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. , 2013, European journal of endocrinology.

[105]  J. Choi,et al.  Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer. , 2013, Thyroid : official journal of the American Thyroid Association.

[106]  L. Indovina,et al.  Determining the appropriate time of execution of an I-131 post-therapy whole-body scan: comparison between early and late imaging , 2013, Nuclear medicine communications.

[107]  Yong Ding,et al.  Radioiodine therapy for patients with differentiated thyroid cancer after thyroidectomy: Direct comparison and network meta-analyses , 2013, Journal of Endocrinological Investigation.

[108]  Quan-Yong Luo,et al.  Value of 131I SPECT/CT for the evaluation of differentiated thyroid cancer: a systematic review of the literature , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[109]  P. Rosário,et al.  Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin. , 2013, Thyroid : official journal of the American Thyroid Association.

[110]  M. Schlumberger,et al.  Progress in molecular-based management of differentiated thyroid cancer , 2013, The Lancet.

[111]  Shu-qi Wu,et al.  Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis. , 2013, The Journal of clinical endocrinology and metabolism.

[112]  K. Frey,et al.  Preablation 131-I scans with SPECT/CT in postoperative thyroid cancer patients: what is the impact on staging? , 2013, The Journal of clinical endocrinology and metabolism.

[113]  S. Larson,et al.  Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. , 2013, The New England journal of medicine.

[114]  M. Barczyński,et al.  Prophylactic central neck dissection for papillary thyroid cancer , 2013, The British journal of surgery.

[115]  S. Dwivedi,et al.  A randomized equivalence trial to determine the optimum dose of iodine-131 for remnant ablation in differentiated thyroid cancer , 2012, Nuclear medicine communications.

[116]  M. Schlumberger,et al.  Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma , 2012, Expert review of anticancer therapy.

[117]  J. Franklyn,et al.  Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. , 2012, The New England journal of medicine.

[118]  M. Schlumberger,et al.  Strategies of radioiodine ablation in patients with low-risk thyroid cancer. , 2012, The New England journal of medicine.

[119]  Rathan M. Subramaniam,et al.  18F-FDG Metabolic Tumor Volume and Total Glycolytic Activity of Oral Cavity and Oropharyngeal Squamous Cell Cancer: Adding Value to Clinical Staging , 2012, The Journal of Nuclear Medicine.

[120]  A. Buck,et al.  Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma , 2012, Clinical endocrinology.

[121]  L. Staib,et al.  The utility of I-123 pretherapy scan in I-131 radioiodine therapy for thyroid cancer. , 2012, Thyroid : official journal of the American Thyroid Association.

[122]  H. Yamazaki,et al.  Utility of Additional Delayed Post-Therapeutic 131I Whole-Body Scanning in Patients With Thyroid Cancer , 2012, Clinical nuclear medicine.

[123]  E. Karaagaoglu,et al.  Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer , 2012, Nuclear medicine communications.

[124]  G. Barbesino,et al.  Thyroid lobe ablation with radioactive iodine as an alternative to completion thyroidectomy after hemithyroidectomy in patients with follicular thyroid carcinoma: long-term follow-up. , 2011, Thyroid : official journal of the American Thyroid Association.

[125]  H. Klein.  Radioiodine Dilution Due to Levothyroxine When Using Recombinant Human Thyroid-Stimulating Hormone: Case Report and Discussion , 2011, Clinical nuclear medicine.

[126]  J. Groopman,et al.  Your Medical Mind: How to Decide What Is Right for You , 2011 .

[127]  C. Spencer.  Clinical review: Clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). , 2011, The Journal of clinical endocrinology and metabolism.

[128]  Jin Young Kwak,et al.  Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk. , 2011, Radiology.

[129]  A. Miyauchi,et al.  Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. , 2011, Thyroid : official journal of the American Thyroid Association.

[130]  C. Reiners,et al.  Pulmonary fibrosis in youth treated with radioiodine for juvenile thyroid cancer and lung metastases after Chernobyl , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[131]  K. Togashi,et al.  Delayed Initial Radioactive Iodine Therapy Resulted in Poor Survival in Patients with Metastatic Differentiated Thyroid Carcinoma: A Retrospective Statistical Analysis of 198 Cases , 2011, The Journal of Nuclear Medicine.

[132]  A. Lenzi,et al.  Expression and localization of the sodium/iodide symporter (NIS) in testicular cells , 2011, Endocrine.

[133]  Jeong Won Lee,et al.  The comparison of 131I whole-body scans on the third and tenth day after 131I therapy in patients with well-differentiated thyroid cancer: preliminary report , 2011, Annals of nuclear medicine.

[134]  E. Silberstein.  The problem of the patient with thyroglobulin elevation but negative iodine scintigraphy: the TENIS syndrome. , 2011, Seminars in nuclear medicine.

[135]  L. Ceriani,et al.  Undetectable Thyroglobulin in Patients With Differentiated Thyroid Carcinoma and Residual Radioiodine Uptake on a Postablation Whole-Body Scan , 2011, Clinical nuclear medicine.

[136]  C. Bal,et al.  Long-term outcome of lobar ablation versus completion thyroidectomy in differentiated thyroid cancer , 2011, Nuclear medicine communications.

[137]  E. Gubała,et al.  Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi , 2010, Thyroid research.

[138]  S. Jeong,et al.  Improved Detection of Lung or Bone Metastases with an I-131 Whole Body Scan on the 7th Day After High-Dose I-131 Therapy in Patients with Thyroid Cancer , 2010, Nuclear medicine and molecular imaging.

[139]  M. Mete,et al.  Radiopharmacokinetics of radioiodine in the parotid glands after the administration of lemon juice. , 2010, Thyroid : official journal of the American Thyroid Association.

[140]  E. Hindié,et al.  On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[141]  K. Koral,et al.  Staging of differentiated thyroid carcinoma using diagnostic 131I SPECT/CT. , 2010, AJR. American journal of roentgenology.

[142]  T. Heusner,et al.  Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[143]  M. Uder,et al.  Five months’ follow-up of patients with and without iodine-positive lymph node metastases of thyroid carcinoma as disclosed by 131I-SPECT/CT at the first radioablation , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[144]  E. Cibas,et al.  The Bethesda System for Reporting Thyroid Cytopathology , 2009, Springer International Publishing.

[145]  D. van Nostrand,et al.  Utility of the radioiodine whole-body retention at 48 hours for modifying empiric activity of 131-iodine for the treatment of metastatic well-differentiated thyroid carcinoma. , 2009, Thyroid : official journal of the American Thyroid Association.

[146]  D. van Nostrand,et al.  The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[147]  Shu-Hua Huang,et al.  Appropriate Time for Post-Therapeutic I-131 Whole Body Scan , 2009, Clinical nuclear medicine.

[148]  T. Giordano,et al.  Thyroid carcinoma metastasis to skull with infringement of brain: treatment with radioiodine. , 2009, Thyroid : official journal of the American Thyroid Association.

[149]  D. Lee,et al.  Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[150]  W. Bautz,et al.  Impact of 131I SPECT/Spiral CT on Nodal Staging of Differentiated Thyroid Carcinoma at the First Radioablation , 2008, Journal of Nuclear Medicine.

[151]  K. Frey,et al.  Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma. , 2008, AJR. American journal of roentgenology.

[152]  M. Bailey,et al.  Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post‐surgical 131I ablation therapy for differentiated thyroid carcinoma , 2008, Clinical endocrinology.

[153]  S. Larson,et al.  The value of positron emission tomography (PET) in the management of patients with thyroid cancer. , 2008, Best practice & research. Clinical endocrinology & metabolism.

[154]  W. Oyen,et al.  Guidelines for radioiodine therapy of differentiated thyroid cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[155]  S. Honsawek,et al.  Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma. , 2008, Thyroid : official journal of the American Thyroid Association.

[156]  M. Luster,et al.  EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[157]  H. Joensuu,et al.  Low vs. High Radioiodine Activity to Ablate the Thyroid after Thyroidectomy for Cancer: A Randomized Study , 2008, PloS one.

[158]  E. Silberstein.  Reducing the Incidence of 131I-Induced Sialadenitis: The Role of Pilocarpine , 2008, Journal of Nuclear Medicine.

[159]  T. Pilli,et al.  A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. , 2007, The Journal of clinical endocrinology and metabolism.

[160]  E. Hindié,et al.  Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome. , 2007, Endocrine-related cancer.

[161]  J. Roh,et al.  Total Thyroidectomy Plus Neck Dissection in Differentiated Papillary Thyroid Carcinoma Patients: Pattern of Nodal Metastasis, Morbidity, Recurrence, and Postoperative Levels of Serum Parathyroid Hormone , 2007, Annals of surgery.

[162]  J. Jonklaas,et al.  Outcomes of patients with differentiated thyroid carcinoma following initial therapy. , 2006, Thyroid : official journal of the American Thyroid Association.

[163]  J. Romijn,et al.  The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer. , 2006, European journal of endocrinology.

[164]  S. Larson,et al.  Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[165]  G. Karanikas,et al.  Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients , 2006, Clinical endocrinology.

[166]  G. Doherty,et al.  The so-called stunning of thyroid tissue. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[167]  X. Shu,et al.  MTR and MTRR Polymorphisms, Dietary Intake, and Breast Cancer Risk , 2006, Cancer Epidemiology Biomarkers & Prevention.

[168]  R. Wahl,et al.  Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. , 2006, The Journal of clinical endocrinology and metabolism.

[169]  Mithat Gonen,et al.  Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. , 2006, The Journal of clinical endocrinology and metabolism.

[170]  J. Stockigt.  Thyroid Cancer: A Guide for Patients , 2005 .

[171]  N. Tamaki,et al.  Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[172]  J. Sampalis,et al.  Large remnant 131I ablation as an alternative to completion/total thyroidectomy in the treatment of well-differentiated thyroid cancer. , 2004, Surgery.

[173]  Á. Barroso,et al.  Efficacy of low and high 131I doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on post-operative cervical uptake , 2004, Nuclear medicine communications.

[174]  D. Elkins,et al.  Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction. , 2004, Thyroid : official journal of the American Thyroid Association.

[175]  C. Bal,et al.  Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. , 2004, The Journal of clinical endocrinology and metabolism.

[176]  P. Grigsby,et al.  Preparation of patients with thyroid cancer for 131I scintigraphy or therapy by 1-3 weeks of thyroxine discontinuation. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[177]  N. Carrasco,et al.  Advances in Na+/I− symporter (NIS) research in the thyroid and beyond , 2003, Molecular and Cellular Endocrinology.

[178]  G. Mariani,et al.  Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. , 2003, The Journal of clinical endocrinology and metabolism.

[179]  J. Romijn,et al.  Effects of low‐iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma , 2003, Clinical endocrinology.

[180]  C. Palestro,et al.  Comparison of (123)I and (131)I for whole-body imaging in thyroid cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[181]  D. van Nostrand,et al.  Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. , 2002, Thyroid : official journal of the American Thyroid Association.

[182]  J. Sisson.  Practical dosimetry of 131I in patients with thyroid carcinoma. , 2002, Cancer biotherapy & radiopharmaceuticals.

[183]  S. Larson,et al.  Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. , 2001, Thyroid : official journal of the American Thyroid Association.

[184]  Amy Y. Chen,et al.  The development of breast carcinoma in women with thyroid carcinoma , 2001, Cancer.

[185]  R. Kloos,et al.  Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer , 2001 .

[186]  K. Kim,et al.  Dietary iodine intake and urinary iodine excretion in patients with thyroid diseases. , 2000, Yonsei medical journal.

[187]  B. Weintraub,et al.  A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. , 1999, The Journal of clinical endocrinology and metabolism.

[188]  Sarah H. Taylor,et al.  Incidence of breast carcinoma in women with thyroid carcinoma , 1999, Cancer.

[189]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[190]  P. Ladenson,et al.  Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. , 1998, Cancer.

[191]  J. Garber,et al.  Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. , 1997, The New England journal of medicine.

[192]  B. O'Sullivan,et al.  A comparison of different staging systems predictability of patient outcome , 1997, Cancer.

[193]  I. Mcdougall,et al.  74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. , 1997, Nuclear medicine communications.

[194]  M. Hočevar,et al.  The dynamics of serum thyroglobulin elimination from the body after thyroid surgery. , 1997, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[195]  M. Schlumberger,et al.  Leukaemias and cancers following iodine-131 administration for thyroid cancer. , 1997, British Journal of Cancer.

[196]  I. Hay,et al.  Prognostic factors and management in thyroid cancer--consensus or controversy? , 1996, The Western journal of medicine.

[197]  J. Hanke,et al.  Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[198]  K. Ain.  Papillary thyroid carcinoma : etiology, assessment and therapy , 1995 .

[199]  P. Hall,et al.  Cancer in iodine-131 exposed patients , 1995, Journal of endocrinological investigation.

[200]  P. Barker,et al.  Iodine-131 in breast milk following therapy for thyroid carcinoma. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[201]  R. Tsang,et al.  Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome. , 1994, The British journal of radiology.

[202]  A. Pinchera,et al.  Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[203]  K. Johansen,et al.  Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[204]  J. Norton,et al.  A Simplified Low Iodine Diet in I-131 Scanning and Therapy of Thyroid Cancer , 1988, Clinical nuclear medicine.

[205]  M. Suzuki,et al.  Iodine content of various meals currently consumed by urban Japanese. , 1986, Journal of nutritional science and vitaminology.

[206]  R. Adler,et al.  Low dose radioiodide thyroid ablation in postsurgical patients with thyroid cancer. , 1976, The American journal of medicine.

[207]  R W Raven,et al.  The british association of surgical oncology , 1973, Annals of the Royal College of Surgeons of England.

[208]  J. E. Rall,et al.  Radiation pneumonitis and fibrosis: a complication of radioiodine treatment of pulmonary metastases from cancer of the thyroid. , 1957, The Journal of clinical endocrinology and metabolism.

[209]  Shinichiro,et al.  Carcinoma , 1906, The Hospital.

[210]  M. Ranney,et al.  Beyond the bedside: Clinicians as guardians of public health, medicine and science , 2020, The American Journal of Emergency Medicine.

[211]  D. van Nostrand,et al.  Radioiodine Imaging for Differentiated Thyroid Cancer: Not All Radioiodine Images are Performed Equally. , 2019, Thyroid : official journal of the American Thyroid Association.

[212]  A. Avram,et al.  Differentiated Thyroid Cancer Outcomes After Surgery and Activity-Adjusted 131I Theragnostics , 2019, Clinical nuclear medicine.

[213]  E. Rossi,et al.  Pathology and Immunohistochemistry in Thyroid Tumors , 2018 .

[214]  Kaliszewski,et al.  American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer : The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer , 2017 .

[215]  Eun Sook Kim,et al.  Low-Dose Radioactive Iodine Ablation Is Sufficient in Patients With Small Papillary Thyroid Cancer Having Minor Extrathyroidal Extension and Central Lymph Node Metastasis (T3 N1a) , 2017, Clinical nuclear medicine.

[216]  M. Ali,et al.  Iodine-131 Therapy and Lacrimal Drainage System Toxicity: Nasal Localization Studies Using Whole Body Nuclear Scintigraphy and SPECT-CT. , 2017, Ophthalmic plastic and reconstructive surgery.

[217]  A. Drzezga,et al.  [Taste dysfunction (dysgeusia) and radioiodine therapy of thyroid cancer - Be aware of side effects by antidepressants and sedatives]. , 2017, Nuklearmedizin. Nuclear medicine.

[218]  F. Atkins,et al.  Dosimetrically Determined Prescribed Activity of 131I for the Treatment of Metastatic Differentiated Thyroid Carcinoma , 2016 .

[219]  Rui Huang,et al.  Low- and high-dose radioiodine therapy for low-/intermediate-risk differentiated thyroid cancer: a preliminary clinical trial , 2016, Annals of Nuclear Medicine.

[220]  D. Nostrand.  Surveillance Radioiodine Whole Body Scans , 2016 .

[221]  S. Sherman,et al.  The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. , 2013, The Journal of clinical endocrinology and metabolism.

[222]  D. van Nostrand,et al.  The Benefits and Risks of I-131 Therapy in Patients with Well-Differentiated Thyroid Cancer , 2010 .

[223]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[224]  A. Bockisch,et al.  124I-PET dosimetry in advanced differentiated thyroid cancer: Therapeutic impact , 2007, Nuklearmedizin.

[225]  J. Humm,et al.  Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[226]  E. Baudin,et al.  Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. , 2006, The Journal of clinical endocrinology and metabolism.

[227]  E. Dadachova,et al.  The Na/I symporter (NIS): imaging and therapeutic applications. , 2004, Seminars in nuclear medicine.

[228]  M. Saghari,et al.  Gonadal function in patients with differentiated thyroid cancer treated with (131)I. , 2004, Hellenic journal of nuclear medicine.

[229]  H. Gerstein,et al.  Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. , 2004, The Journal of clinical endocrinology and metabolism.

[230]  C. Bal,et al.  Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma. , 1996, Cancer.

[231]  M. Dottorini,et al.  Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[232]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[233]  M. Sonenberg,et al.  The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. , 1962, The American journal of roentgenology, radium therapy, and nuclear medicine.

[234]  P DESAIVE,et al.  [Thyroid cancer]. , 1951, Revue medicale de Liege.